ArticleSeminars in ophthalmology2021
Nerve Growth Factor as an Ocular Therapy: Applications, Challenges, and Future Directions.
Article in Seminars in ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects.CNS drugs · 2023Trial
- Nerve Growth Factor Treatment and the Corneal Epithelium: Extracellular Vesicle-Mediated Signaling.Journal of extracellular biology · 2026Article
- Aptamer-Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies.Advanced healthcare materials · 2026Review
- Pituitary adenylate cyclase-activating polypeptide (PACAP) promotes regeneration of corneal epithelial cells possibly via the NR4A1 signaling pathway.Scientific reports · 2026Article
- Nerve Growth Factor in Diabetes Mellitus: Pathophysiological Mechanisms, Biomarkers and Therapeutic Opportunities.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings.PNAS nexus · 2025Article
- Uptake Inhibition to Improve Bioavailability of Nanoparticle-Mediated Growth Factor Delivery to the Corneal Epithelium.ACS pharmacology & translational science · 2025Article
- The Role of Nerve Growth Factor on the Ocular Surface: A Review of the Current Experimental Research and Clinical Practices.International journal of molecular sciences · 2025Review
- Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis.Drugs · 2025Review
- Influence of Functional Variations in Genes of Neurotrophins and Neurotransmitter Systems on the Development of Retinopathy of Prematurity.International journal of molecular sciences · 2025Article
- 1953-2023. Seventy Years of the Nerve Growth Factor: A Potential Novel Treatment in Neurological Diseases?Aging and disease · 2024Review
- The History of Nerve Growth Factor: From Molecule to Drug.Biomolecules · 2024Review
- Review
- Review
- Article
- AAV2/9-mediated gene transfer into murine lacrimal gland leads to a long-term targeted tear film modification.Molecular therapy. Methods & clinical development · 2022Article
- Superparamagnetic Iron Oxide Nanoparticles and Curcumin Equally Promote Neuronal Branching Morphogenesis in the Absence of Nerve Growth Factor in PC12 Cells.Pharmaceutics · 2022Article
- Corneal stromal repair and regeneration.Progress in retinal and eye research · 2022Review
- Role of NGF and its receptors in wound healing (Review).Experimental and therapeutic medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nerve growth factor (NGF), the prototypical neurotrophin first discovered in the 1950s, has recently garnered increased interest as a therapeutic agent promoting neuronal health and regeneration. After gaining orphan drug status within the last decade, NGF-related research and drug development has accelerated. The purpose of this article is to review the preclinical and clinical evidence of NGF in various applications, including central and peripheral nervous system, skin, and ophthalmic disorders. We focus on the ophthalmic applications including not only the FDA-approved indication of neurotrophic keratitis but also retinal disease and glaucoma. NGF represents a promising therapy whose therapeutic profile is evolving. The challenges related to this therapy are reviewed, along with possible solutions and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.